免疫系统
乳腺癌
癌症
医学
肿瘤科
免疫学
癌症研究
内科学
生物
作者
Victoria C. Rayson,Michael A. Harris,Peter Savas,Michael L. Hun,Balaji Virassamy,Roberto Salgado,Sherene Loi
标识
DOI:10.1016/j.trecan.2024.02.008
摘要
Abstract
Triple-negative breast cancers (TNBCs) exhibit heightened T cell infiltration, contributing to an enhanced response to immune checkpoint blockade (ICB) compared with other subtypes. An immune-rich immune microenvironment correlates with improved prognosis in early and advanced TNBC. Combination chemotherapy and ICB is now the standard of care in early- and late-stage TNBC. Although programmed death ligand-1 (PD-L1) positivity predicts ICB response in advanced stages, its role in early-stage disease remains uncertain. Despite neoadjuvant ICB becoming common in early-stage TNBC, the necessity of adjuvant ICB after surgery remains unclear. Understanding the molecular basis of the immune response in breast cancer is vital for precise biomarkers for ICB and effective combination therapy strategies.
科研通智能强力驱动
Strongly Powered by AbleSci AI